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OBJECTIVES We explored whether there are gender differences in cardiac remodeling and whether etiology
influences organ and cellular remodeling in advanced heart failure (HF).
BACKGROUND Several studies have shown a survival benefit for women compared to men with symptomatic
HF. This observation may be related to gender differences in cardiac remodeling.
METHODS We studied hearts from 100 patients (72 men and 28 women) receiving cardiac transplan-
tation at our institution. Cardiac morphology was assessed with echocardiography and direct
measurement of cardiac mass. Cardiac myocyte volume, length, width, cross-sectional area,
and contraction were measured using previously validated techniques.
RESULTS Among 50 patients with idiopathic cardiomyopathy (CM), we observed no gender-based
differences in cardiac or cellular remodeling. In contrast, among 50 patients with ischemic
cardiomyopathy (ICM), the heart weight index was significantly greater in men, and there
was a strong trend toward an increased left ventricular (LV) mass index as well. These gender
differences in cardiac and LV mass were paralleled by marked gender differences in myocyte
volume, such that average myocyte volume was 36% greater in men than in women, in
association with a 14% increase in resting cell length.
CONCLUSIONS Our studies demonstrate a multilevel gender difference in post-infarction remodeling, with
women exhibiting reduced hypertrophy. Our studies further demonstrate that gender
differences in cardiac remodeling in ICM are largely related to fundamental differences in
cellular remodeling rather than simply differences in infarct size or expansion. Distinctions
observed between ischemic and idiopathic CM suggest that gender may influence local
myocardial responses to injury. (J Am Coll Cardiol 2003;41:300–6) © 2003 by the
American College of Cardiology Foundation
The syndrome of heart failure (HF) and its sequelae are
significant health problems in the U.S. and worldwide.
Despite recent therapeutic advances, the mortality from
symptomatic HF remains nearly 50%, and this diagnosis is
responsible for significant morbidity and associated health
care costs (1–4). Data obtained from the Framingham
database indicate the median survival associated with symp-
tomatic HF differs on the basis of gender, with reported
values of 1.7 years for men and 3.2 years for women (1,4).
In the FIRST study, the investigators reported a similar
survival advantage for women but observed this difference
exclusively among patients with an idiopathic cardiomyop-
athy (CM) (5). This finding suggests that the etiology of
HF may affect the prognostic influence of gender (5,6).
Studies conflict about whether there is a gender difference in
mortality among patients with an ischemic cardiomyopathy
(ICM), with some studies indicating a higher mortality for
women (7–10) and others observing no gender difference
(11,12).
Although few clinical studies have examined the biologic
mechanisms responsible for the clinically observed gender
differences in HF mortality, animal studies have shown
differences in the progression toward decompensated HF.
Lorell and collaborators have reported differences in global
left ventricular (LV) remodeling, cardiac myocyte hypertro-
phy, and associated changes in gene expression in rats, with
pressure overload hypertrophy induced by aortic banding
(13,14). Similarly, studies in genetically hypertensive rats
have shown gender differences in cardiac myocyte remod-
eling during the progression from the baseline state,
through compensated concentric hypertrophy, to advanced
HF with eccentric hypertrophy (15). To date, no studies
have addressed whether gender influences cellular remodel-
ing among humans. Therefore, in a group of patients with
advanced HF requiring cardiac transplantation, we explored
whether there are gender differences in cardiac and cellular
remodeling and whether the etiology of HF influences
myocardial remodeling. On the basis of studies showing
equivalent cardiac myocyte hypertrophy in rats with decom-
pensated HF, we hypothesized that there would be no
gender difference in humans with advanced HF requiring
cardiac transplantation.
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METHODS
Study design. Over a 38-month period from February
1996 through April 1999, a total of 205 orthotopic heart
transplants were performed at our institution. In 152 of
these patients, we were able to obtain large quantities of
isolated cardiac myocytes suitable for detailed morphologic
examination using recently described techniques (16). After
excluding cases with prior mechanical circulatory support,
there were 50 patients with idiopathic dilated cardiomyop-
athy (IDC) diagnosed in accordance with World Health
Organization criteria and 50 patients with advanced CM
due to coronary artery disease and previous myocardial
infarction (MI). Clinical data, including information about
the diagnosis, complications, and treatment of HF, were
obtained at the time of transplantation. The duration of HF
was defined as the time between the first diagnosis of HF
and the time of transplantation. For patients with ICM, the
time between their first MI and the time of cardiac
transplantation was recorded. This protocol was reviewed by
the Temple University Institutional Review Board and was
determined to be exempt in accordance with paragraph 4
(protection of human subjects, title 5, Code of Federal
Regulations, part 46), pertaining to research involving
pathological specimens.
Menopausal status. Clinical information regarding the
gynecologic history and menopausal status of each woman
was obtained retrospectively using a telephone question-
naire. The same interviewer (K. B. M.) administered all
questionnaires. The participants were asked information
regarding their use of hormone replacement therapy (HRT)
and menopausal status at the time of transplant. The
women were queried regarding the onset of irregular men-
strual cycles and cessation of menses in relation to the date
of transplant. Menopause was defined as cessation of men-
ses for 12 months. On the basis of medical records and
phone-based interviews, menopausal and HRT status at the
time of transplant could be determined for 22 of 28 women
in the study cohort. On the basis of age 55 years,
menopausal status could be assumed for four of the six
women unavailable for interview (17), but hormone and
HRT status remained unknown for these women.
Echocardiographic assessment. Echocardiograms were
obtained from patients by experienced sonographers using a
Hewlett-Packard Sonos 1500 machine (Hewlett-Packard,
Anasco, California) and a 2.5 MHz transducer. Left ven-
tricular dimensions were obtained using the parasternal
short-axis view at the level of the papillary muscle. M-mode
measurements were obtained using the leading-edge tech-
nique in accordance with recommendations from the Amer-
ican Society of Echocardiography. Left ventricular mass was
calculated using the following formula validated by De-
vereux et al. (18):
LV mass g  0.80  1.04 IVS  LVEDD  PWT3
 LVEDD3  0.6
where IVS  interventricular septal dimension, LVEDD 
left ventricular end-diastolic dimension, and PWT  pos-
terior wall thickness dimension.
Left ventricular mass index was calculated by dividing LV
mass by body surface area.
The left ventricular ejection fraction (LVEF) was calcu-
lated using the following equation (19):
LVEF  LVEDD2 LVESD2/LVEDD2
where LVESD  left ventricular end-systolic dimension.
Relative wall thickness was calculated using the following
ratio:
Relative wall thickness  2  PWT/LVEDD
Hemodynamics. Right heart catheterization was per-
formed on each patient immediately before cardiac trans-
plantation, and intracardiac filling pressures were measured.
Right atrial, pulmonary artery, and pulmonary capillary
pressure were measured directly using a balloon-tipped
pulmonary artery catheter (American Edwards Laborato-
ries, AHS del Caribe, Inc.). Cardiac output was measured
using the thermodilution technique. Cardiac index was
calculated by dividing cardiac output by body surface area.
Arterial pressure was measured invasively.
Myocyte isolation technique. Cardiac myocytes were iso-
lated from all patients using the following procedure.
Briefly, at the time of transplant, the aorta was cross-
clamped and the aortic root was immediately perfused with
a cold-blood-buffered cardioplegic solution. After 10 to 30
min of cross-clamping, the heart was explanted and taken to
the experimental laboratory. All hearts were weighed before
initiation of the cell isolation protocol. Upon arrival, an
epicardial vessel was cannulated and perfused with Krebs-
Henseleit buffer. The perfused region of the heart was
excised and rinsed with a calcium-free solution containing
Krebs-Henseleit buffer with taurine (10 mM). The myocar-
dial region selected for isolation was perfused for 30 min
with a recirculation solution containing type II collagenase
(180 U/ml), 2,3-butanedione monoxamine (20 mM), tau-
rine (20 mM), and calcium chloride (0.05 mM). The tissue
underwent a second exposure to a nonrecirculating rinse for
10 min with Krebs-Henseleit buffer solution containing
Abbreviations and Acronyms
CM  cardiomyopathy
HF  heart failure
HRT  hormone replacement therapy
IDC  idiopathic dilated cardiomyopathy
ICM  ischemic cardiomyopathy
IVS  interventricular septal dimension
LV  left ventricular
LVEF  left ventricular ejection fraction
LVEDD  left ventricular end-diastolic dimension
MI  myocardial infarction
PWT  posterior wall thickness dimension
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taurine (10 mM), 2,3-butanedione monoxamine (20 mM),
and calcium chloride (0.2 mM). The tissue was then
removed from the cannula and a mid-myocardial region was
minced in the rinse solution. In hearts with ICM, isolated
myocytes were obtained from viable myocardium as far as
possible from previous MIs. The resulting cell suspension
was filtered and centrifuged (25  G). The cells were
resuspended in a Krebs-Henseleit solution containing 1%
weight/volume bovine albumin, taurine (10 mM), and
calcium chloride (0.2 mM). All solutions bubbled with 95%
O2 and 5% CO2 and kept at 37°C and pH 7.4. The yield of
calcium-tolerant rod-shaped myocytes using this protocol
ranged from 10% to 60% with this cell isolation protocol.
Cell morphology analysis. An aliquot of cells was fixed in
an iso-osmotic solution containing 1.5% glutaraldehyde in
0.06 mol/l phosphate buffer. As shown by Gerdes et al. (20),
this fixation method does not alter myocyte volume. Fixed
cells were centrifuged through a Ficoll gradient to remove
unwanted debris and cell fragments. For each heart studied,
median myocyte volume was measured from a cell suspen-
sion containing at least 10,000 myocytes using Coulter
Channelyzer analysis as previously described (16,20). Pre-
vious studies have demonstrated that inclusion of round
cells does not significantly alter the final cell volume (20).
From the same suspensions of fixed myocytes, evaluations of
myocyte length and profile area were performed using a
microscope, a charge-coupled device camera, and a frame
grabber. After calibration using a stage micrometer, cell
length and cell profile area were measured in 60 to 100 cells.
Using NIH image software (version 1.59), myocyte length
was measured as the longitudinal axis of the best-fitting
ellipse. The average cell width was calculated using the ratio
of the profile area to the length of the cell. For each heart
studied, the average myocyte cross-sectional area was calcu-
lated as the ratio of median cell volume to mean cell length
as previously described (20). Because normal adult myocyte
size is consistent across mammalian species, morphometric
data were not scaled to body size.
Cellular function studies. Cellular physiologic analysis of
isolated human cells was conducted using a video edge
detection system (Crescent Electronics, Sandy, Utah). All
cells were perfused using Krebs-Henseleit buffered solution
during the physiologic measurements. Myocyte contractions
were assessed via field stimulation at 0.5 Hz and 37°C.
Myocyte contraction magnitude was normalized to the
diastolic cell length and expressed as a percentage of resting
cell length (fractional cell shortening). The time to 50%
relaxation was measured as the interval between the stimu-
lus and the achievement of 50% relengthening.
Statistical analysis. Comparisons were made on organ and
cellular morphologic parameters using a two-factor (etiolo-
gy, gender) and three-factor (etiology, gender, diabetes/
hypertension/pharmacologic therapy) analysis of variance
with follow-up pairwise comparisons using Bonferroni ad-
justment. In addition, cell volume data were also examined
using analysis of covariance to adjust for age or heart
weight/body weight index. Intergroup differences in meno-
pausal status were explored using chi-square analysis. To
explore relationships between two continuous variables,
simple linear regression analyses were performed. In all
cases, statistical significance was defined as p  0.05.
RESULTS
Clinical characteristics. GENERAL. Within each etiologic
subgroup, clinical characteristics of patients included in this
study are shown in Table 1. There were no differences
between mean age of men and women. Among patients
with IDC, a history of diabetes mellitus and hypertension
were observed more frequently among women, whereas a
history of atrial fibrillation was observed more frequently
among men. Among patients with ICM, the number of
years that had elapsed since the first MI was greater for men
than for women, although the durations of clinical HF and
other historic variables were not significantly different.
Medication use at the time of transplantation did not differ
Table 1. Clinical Data Grouped by Etiology and Gender
IDC Patients ICM Patients
Male
(n  35)
Female
(n  15) p Value
Male
(n  37)
Female
(n  13) p Value
Age, yrs 52 	 2 53 	 3 0.754 59 	 1 58 	 2 0.399
Hx of DM, % 9 33 0.029 27 46 0.204
Hx of HTN, % 20 53 0.018 57 62 0.764
Hx of clinical VT, % 37 13 0.092 35 15 0.181
Hx of chronic Afib, % 23 0 0.043 22 0 0.067
Hx of CABG, % N/A N/A N/A 54 54 0.990
CHF duration, months 70 	 8 57 	 11 0.380 27 	 6 19 	 8 0.429
Years since first MI N/A N/A N/A 12.5 	 1.4 6.6 	 1.5 0.025
Medications at transplant
Diuretic, % 60 60 0.999 57 92 0.020
Antiarrhythmic, % 17 7 0.328 27 0 0.036
Data for continuous variables are expressed as mean 	 SEM.
Afib  atrial fibrillation; CABG  coronary artery bypass grafting; CHF  congestive heart failure; DM  diabetes mellitus;
HTN  hypertension; Hx  history; ICM  ischemic cardiomyopathy; IDC  idiopathic dilated cardiomyopathy; MI 
myocardial infarction; VT  ventricular tachycardia.
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between men and women with idiopathic CM, but among
patients with ICM, there was greater use of diuretics among
women and greater use of antiarrhythmics among men.
MENOPAUSAL STATUS. Eight of 15 women with idiopathic
CM and nine of 13 patients with ICM were post-
menopausal (p  ns). When HRT was taken into account,
only 7 of 13 women with ICM and 4 of 15 women with
idiopathic CM were post-menopausal and without estrogen
supplementation (p  ns). When known, the age at the
time of menopause was similar regardless of the etiology of
HF: idiopathic vs. ICM (46.1 	 1.7 years vs. 48.9 	 1.3
years) (p  ns). There were no significant differences
observed in any of the cellular indices measured between
HRT users and nonusers.
Cardiac morphology. Data describing cardiac and cell
morphology in each of the etiologic subgroups are presented
in Table 2. Among patients with idiopathic CM requiring
cardiac transplantation, hearts from men and women exhib-
ited remarkable similarity for all organ and cellular morpho-
logic variables assessed. Of note, significant gender differ-
ences in raw values for heart weight, LV mass, LVEDD,
and LVESD (data not shown) all became equivalent after
these variables were normalized for body surface area. For
patients with ICM, several important differences in cardiac
morphology were observed. Specifically, the heart weight
index was significantly greater in men (p  0.018), and
there was a strong trend toward an increased LV mass index
as well. In addition, although there were no gender differ-
ences in indexed chamber dimensions or wall thickness,
relative wall thickness tended to be higher in women with
ICM compared with their male counterparts.
For patients with ICM, gender differences in cardiac and
LV mass were paralleled by marked gender differences in
myocyte volume such that average myocyte volume was 36%
greater in men than in women. Further morphologic anal-
ysis revealed that the greater cell volume among men was a
reflection of a significantly greater (14%) average cell length
and a nonsignificantly greater (18%) myocyte cross-sectional
area. The average values for median cell volume among
women and men with ICM are compared with historical
data from nonfailing nonhypertensive controls in Figure 1
(16). Although the time between first MI and time to
transplantation was shorter among women compared to
men, this difference did not correlate with cellular remod-
eling indices such as cell volume, using simple linear
regression for analysis, as shown in Figure 2.
Analysis of potential confounding factors. Based on the
three-factor analysis of variance (using Bonferroni adjust-
ment, 28 comparisons), the gender difference in cellular
remodeling among patients with ICM could not be attrib-
uted to differences in the proportion of patients with
diabetes or hypertension (p  1.0). Similarly, differences in
pharmacologic inhibition of renin-angiotensin system by
angiotensin II receptor blocker (p  1.0) or angiotensin-
converting enzyme inhibitors (p  0.27) could not
account for the observed gender differences in cardiac
myocyte morphology among patients with ICM. In
addition, when cell volume data were adjusted for either
age (p  0.01) or heart weight index (p  0.049), analysis
of covariance (using 6 comparisons) confirmed a gender
difference in myocyte volume that was limited to those
patients with ICM.
Cardiac function. Analysis of hemodynamic and function
data was performed. With the exception of a somewhat
higher right atrial pressure among women with idiopathic
CM, cardiac hemodynamic measurements were equivalent
among men and women in the two etiologic groups. Within
both the ischemic and idiopathic groups, we observed no
gender differences in isolated myocyte fractional shortening
or time to 50% relaxation (data not shown).
Table 2. Cardiac and Myocyte Morphology Data Grouped by Etiology and Gender
IDC Patients ICM Patients
Male
(n  35)
Female
(n  15)
p
Value
Male
(n  37)
Female
(n  13)
p
Value
Heart weight index, g/m2 291 	 12 295 	 28 0.863 290 	 9 249 	 11 0.018
Echocardiographic data
LV mass index, g/m2 180 	 12 170 	 20 0.649 169 	 8 139 	 10 0.060
LV EDD index, cm/m2 3.9 	 0.1 4.2 	 0.3 0.273 3.9 	 0.1 3.7 	 0.1 0.554
LV ESD index, cm/m2 3.4 	 0.2 3.7 	 0.3 0.209 3.2 	 0.1 3.0 	 0.1 0.273
Septal wall thickness, cm 0.93 	 0.03 0.83 	 0.05 0.057 0.90 	 0.03 0.86 	 0.06 0.524
Posterior wall thickness, cm 0.92 	 0.02 0.87 	 0.05 0.271 0.91 	 0.03 0.90 	 0.04 0.798
Relative wall thickness 0.26 	 0.02 0.25 	 0.02 0.630 0.25 	 0.01 0.28 	 0.02 0.069
Cellular data
Myocyte volume, 1,000  m3 48.5 	 2.2 47.4 	 3.4 0.780 52.0 	 2.5 38.2 	 2.3 0.003
Myocyte length, m 219 	 6 208 	 6 0.284 199 	 5 174 	 7 0.010
Myocyte width, m 32 	 1 31 	 1 0.928 32 	 1 30 	 1 0.176
Myocyte CSA, m2 223 	 10 234 	 22 0.626 263 	 13 223 	 14 0.099
Data for continuous variables are expressed as mean 	 SEM.
CSA  cross-sectional area; EDD  end-diastolic diameter; ESD  end-systolic diameter; ICM  ischemic cardiomyopathy; IDC  idiopathic dilated cardiomyopathy;
LV  left ventricular.
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DISCUSSION
The present study examined whether there are gender
differences in cardiac remodeling among humans with
end-stage HF. Among patients with advanced idiopathic
CM, we observed equivalent degrees of eccentric cardiac
hypertrophy among men and women, with an overall
pattern similar to that previously reported in animal models
of advanced HF due to pressure overload. In contrast,
among patients with ICM, we observed a significant gender
difference in the magnitude of cardiac hypertrophy that has
not been previously reported. By employing human cardiac
myocyte isolation and morphologic analysis (16), our studies
further demonstrate that gender differences in cardiac re-
modeling in ICM are largely related to fundamental differ-
ences in cellular remodeling rather than simply differences
in infarct size or expansion. Furthermore, the distinctions
Figure 1. Average myocyte volume for nonhypertensive, nonfailing hearts (n  8), and ischemic cardiomyopathy (ICM) hearts from men (n  37), and
women (n  13). The data for the nonfailing hearts is an historical control group previously reported in reference 16. Data are mean 	 SEM. p  0.05
for both ICM males and females.
Figure 2. Scatterplot depicting the relationship between myocyte volume and number of year since the first myocardial infarction (MI) among patients with
ischemic cardiomyopathy (n  50). As indicated numerically within the plot, simple linear regression analysis revealed no significant relationship between
these variables.
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observed between advanced idiopathic CM and advanced
ICM suggest that local myocardial responses to injury may
contribute to the gender differences observed among pa-
tients with ICM.
Among patients with inotrope-dependent idiopathic
CM, we observed no qualitative or quantitative gender
differences in cardiac hypertrophy. This morphologic equiv-
alence among men and women with idiopathic CM was
observed using four separate types of analytic techniques: 1)
direct measurement of heart weight, 2) echocardiographic
estimation of LV mass, 3) Coulter Channelyzer determina-
tion of median cell volume, and 4) direct morphologic
analysis of isolated cardiac myocytes. Our decision to index
organ level parameters to body size is supported by this
multilevel morphologic equivalence and by conventions
established in previous reports (15,20). Of note, the nearly
identical degrees of organ and cellular eccentric hypertrophy
occurred despite a higher prevalence of hypertension and
diabetes among females with idiopathic CM. Although we
are aware of no similar analysis in humans, prior studies in
animal models of chronic pressure overload suggest some
similarities. Specifically, in spontaneously hypertensive rats
developing HF and eccentric hypertrophy, Tamura et al.
(15) reported equivalent chamber dilation, cardiac hypertro-
phy, and cellular hypertrophy in male and female animals.
Although significant gender differences were observed at
earlier time points before HF developed, in this and other
studies (13,15), the morphologic equivalence once decom-
pensated HF developed is quite similar to our findings in
idiopathic CM at both the organ and cellular levels.
In contrast, we report for the first time a striking gender
difference in post-infarction cardiac remodeling among
patients with advanced, inotrope-dependent ICM. Using
the same body size normalization that was applied to
patients with idiopathic CM, we observed a significantly
greater heart weight index among men with ICM. More-
over, LV mass index derived using different methodology
suggested a gender difference of similar magnitude. A recent
population-based analysis of gender-specific differences in
cardiac remodeling in patients with LV dysfunction, dem-
onstrated an attenuated degree of hypertrophy among fe-
male subjects (21). Our cellular morphology data support
and extend the gender differences observed at the organ level
among patients with ICM. Specifically, the degree of
post-infarction cellular hypertrophy among men was nearly
twice that observed among women on the basis of cell
volume analysis and comparison to myocytes from nonfail-
ing, nonhypertensive controls. Although the time since the
first MI was longer for men in our study, even among
women the average interval was 6.6 years. Moreover, regres-
sion analysis did not support any significant relationship
between indices of cellular hypertrophy and the time since
the first infarction. From a mechanistic standpoint, these
differences in cellular remodeling suggest that the gender
differences in organ mass and morphology reflect funda-
mental differences in cellular remodeling in the noninfarcted
myocardium rather than differences in the remodeling of
infarcted tissue or the peri-infarct zone.
The contrast between the gender differences in post-
infarction hypertrophy and the lack of such differences
among patients with idiopathic CM is an intriguing aspect
of these studies. Neither clinical variables nor hemodynamic
data obtained at the time of transplantation suggest any
extracardiac explanation for this etiologic distinction. Alter-
natively, it seems more likely that local myocardial factors
such as responses to injury, chronic ischemia, or paracrine
effects of interstitial or infarcted myocardium could contrib-
ute to the apparent interaction between etiology and gender
in these studies. This speculation is based on the established
ability of interstitial cells to generate cytokines and growth
factors such as angiotensin II and endothelin that modulate
myocyte growth in vitro. From this perspective, the
etiology-based gender differences we observed could indi-
rectly reflect gender differences in myocyte responses to
myocardial growth modulators.
Our findings do not necessarily support an estrogen-
mediated difference in post-infarction remodeling. Al-
though there are estrogen receptors in the heart (22), most
of the women in the ICM group were post-menopausal, and
the proportion receiving HRT was equivalent to the pro-
portion observed among the women with idiopathic CM.
The lack of a relationship between menopausal status or
HRT and the observed differences in cellular hypertrophy in
patients with ICM is consistent with the interpretation that
gender differences in cardiac remodeling may not be
estrogen-dependent. Indeed, recent clinical trials show no
benefit from HRT in the progression of cardiovascular
disease (23–25), yet a survival benefit has been consistently
reported for women with HF compared with men (26,27).
The estimated age of menopause for women in this cohort
of patients with advanced HF was less than the median age
reported in the U.S. (17,28), but the significance of this
finding is unclear.
Despite the novelty of our findings, several limitations of
this research deserve mention. First, the remodeling pat-
terns observed among the most severely myopathic patients
who require transplantation may not be representative of the
remodeling that occurs in patients with less severe disease.
Second, the observed differences in end-stage CM offer no
insight on the evolution of the remodeling patterns ob-
served. For example, it is possible that significant gender
differences exist in idiopathic CM before the development
of end-stage HF, as has been reported in genetically
hypertensive rats (15). Finally, although men and women in
each etiologic subgroup had similar medications and hemo-
dynamics at the time of transplantation, this does not
exclude possible differences in these variables during the
years of evolving CM.
In conclusion, the present studies demonstrate significant
gender-related differences in cardiac and cellular remodeling
among patients with end-stage ICM. Our findings support
the general hypothesis that gender-based differences in
305JACC Vol. 41, No. 2, 2003 Crabbe et al.
January 15, 2003:300–6 Gender Differences in Cardiac Remodeling
myocardial biology contribute to recently reported gender
differences in clinical outcomes and therapeutic responses
following MI. Further studies are required to more com-
pletely explore the evolution of post-infarction remodeling
and to identify the mechanisms through which gender
modulates myocardial remodeling.
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